WO2009030237A3 - Methods for recombinant manufacturing of anti-rsv antibodies - Google Patents

Methods for recombinant manufacturing of anti-rsv antibodies Download PDF

Info

Publication number
WO2009030237A3
WO2009030237A3 PCT/DK2008/050218 DK2008050218W WO2009030237A3 WO 2009030237 A3 WO2009030237 A3 WO 2009030237A3 DK 2008050218 W DK2008050218 W DK 2008050218W WO 2009030237 A3 WO2009030237 A3 WO 2009030237A3
Authority
WO
WIPO (PCT)
Prior art keywords
rsv
collection
antibodies
cells
rsv antibodies
Prior art date
Application number
PCT/DK2008/050218
Other languages
French (fr)
Other versions
WO2009030237A2 (en
Inventor
Anne Bondgaard Tolstrup
Johan Lantto
Finn Wiberg
Lars Soegaard Nielsen
Original Assignee
Symphogen As
Anne Bondgaard Tolstrup
Johan Lantto
Finn Wiberg
Lars Soegaard Nielsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As, Anne Bondgaard Tolstrup, Johan Lantto, Finn Wiberg, Lars Soegaard Nielsen filed Critical Symphogen As
Priority to AU2008295248A priority Critical patent/AU2008295248A1/en
Priority to CA2695309A priority patent/CA2695309A1/en
Priority to BRPI0817079A priority patent/BRPI0817079A2/en
Priority to JP2010523277A priority patent/JP2011514139A/en
Priority to MX2010002044A priority patent/MX2010002044A/en
Priority to CN200880106131A priority patent/CN101821289A/en
Priority to EP08784476A priority patent/EP2185590A2/en
Publication of WO2009030237A2 publication Critical patent/WO2009030237A2/en
Publication of WO2009030237A3 publication Critical patent/WO2009030237A3/en
Priority to ZA2010/00756A priority patent/ZA201000756B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to a method for manufacturing recombinant anti-RSV antibodies and antibody compositions. The method comprises obtaining a collection of cells transfected with a collection of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one distinct anti-RSV antibody. The cells are cultured under suitable conditions for expression of the anti-RSV antibody/antibodies. The nucleic acid sequence is introduced into the cells by transfection with expression vectors, which avoid site-specific integration. The present method is suitable for manufacturing recombinant mono- and polyclonal anti-RSV antibodies for therapeutic uses.
PCT/DK2008/050218 2007-09-07 2008-09-04 Methods for recombinant manufacturing of anti-rsv antibodies WO2009030237A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2008295248A AU2008295248A1 (en) 2007-09-07 2008-09-04 Methods for recombinant manufacturing of anti-RSV antibodies
CA2695309A CA2695309A1 (en) 2007-09-07 2008-09-04 Methods for recombinant manufacturing of anti-rsv antibodies
BRPI0817079A BRPI0817079A2 (en) 2007-09-07 2008-09-04 processes for recombinant manufacture of anti-rsv antibodies
JP2010523277A JP2011514139A (en) 2007-09-07 2008-09-04 Method for recombinant production of anti-RSV antibodies
MX2010002044A MX2010002044A (en) 2007-09-07 2008-09-04 Methods for recombinant manufacturing of anti-rsv antibodies.
CN200880106131A CN101821289A (en) 2007-09-07 2008-09-04 Methods for recombinant manufacturing of anti-rsv antibodies
EP08784476A EP2185590A2 (en) 2007-09-07 2008-09-04 Methods for recombinant manufacturing of anti-rsv antibodies
ZA2010/00756A ZA201000756B (en) 2007-09-07 2010-02-01 Methods for recombinant manufacturing of anti-rsv antibodies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200701289 2007-09-07
DKPA200701289 2007-09-07
US97140407P 2007-09-11 2007-09-11
US60/971,404 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009030237A2 WO2009030237A2 (en) 2009-03-12
WO2009030237A3 true WO2009030237A3 (en) 2009-04-30

Family

ID=40297785

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/050218 WO2009030237A2 (en) 2007-09-07 2008-09-04 Methods for recombinant manufacturing of anti-rsv antibodies

Country Status (13)

Country Link
US (2) US20090137003A1 (en)
EP (1) EP2185590A2 (en)
JP (1) JP2011514139A (en)
KR (1) KR20100087283A (en)
CN (1) CN101821289A (en)
AU (1) AU2008295248A1 (en)
BR (1) BRPI0817079A2 (en)
CA (1) CA2695309A1 (en)
MX (1) MX2010002044A (en)
RU (1) RU2010113510A (en)
TW (1) TW200925279A (en)
WO (1) WO2009030237A2 (en)
ZA (1) ZA201000756B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007262635B2 (en) * 2006-06-23 2014-09-11 Adc Therapeutics Sa Polynucleotides and polypeptide sequences involved in cancer
ES2369946T3 (en) * 2007-03-01 2011-12-09 Symphogen A/S PROCEDURE FOR CLONING ANALOG ANTIBODIES.
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20100069262A1 (en) * 2008-08-29 2010-03-18 Symphogen A/S Method for Cloning Avian-Derived Antibodies
AU2009321508B2 (en) 2008-11-03 2015-03-12 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EA023179B1 (en) * 2009-08-13 2016-05-31 Круселл Холланд Б.В. Antibodies against human respiratory syncytial virus (rsv) and methods of use
AU2009353693B2 (en) * 2009-10-06 2016-07-21 Medimmune Ltd RSV-specific binding molecule
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN104628850B (en) * 2009-10-06 2020-07-28 医学免疫有限公司 RSV-specific binding molecules
CN104131035A (en) 2009-12-10 2014-11-05 瑞泽恩制药公司 Mice that make heavy chain antibodies
KR101896124B1 (en) 2010-07-09 2018-09-07 얀센 백신스 앤드 프리벤션 비.브이. Anti-human respiratory syncytial virus(rsv) antibodies and methods of use
BR112013025198A2 (en) 2011-03-31 2018-12-04 Alethia Biotherapeutics Inc. kidney-associated antigen 1 antibodies and antigen-binding fragments thereof
PL2802351T3 (en) 2012-01-09 2019-11-29 Adc Therapeutics Sa Agents for treating triple negative breast cancer
TR201900694T4 (en) * 2012-08-23 2019-02-21 Agensys Inc Antibody drug conjugates (ADC) that bind to 158p1d7 proteins.
JP5996707B2 (en) * 2015-04-15 2016-09-21 メディミューン リミテド RSV specific binding molecule
MA42043A (en) 2015-05-07 2018-03-14 Agenus Inc ANTI-OX40 ANTIBODIES AND METHODS OF USE THEREOF
WO2017096281A1 (en) * 2015-12-02 2017-06-08 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
CA3006963A1 (en) * 2015-12-03 2017-06-08 Ludwig Institute For Cancer Research Ltd. Anti-ox40 antibodies and methods of use thereof
SG11201903287PA (en) * 2016-10-21 2019-05-30 Adimab Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018075974A2 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
MA46770A (en) 2016-11-09 2019-09-18 Agenus Inc ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
WO2018150029A1 (en) * 2017-02-17 2018-08-23 Institut Pasteur Generation of monoclonal antibodies targeting respiratory syncytial virus (rsv) using regulatory b cells from newborns (nbregs)
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
WO2021253002A1 (en) 2020-06-12 2021-12-16 Gigagen, Inc. Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
WO2022031834A1 (en) * 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007853A2 (en) * 2004-07-20 2006-01-26 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
WO2007065433A2 (en) * 2005-12-05 2007-06-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
WO2008106980A2 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
WO2008145133A2 (en) * 2007-05-25 2008-12-04 Symphogen A/S Method for manufacturing a recombinant polyclonal protein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
EP1771483A1 (en) * 2004-07-20 2007-04-11 Symphogen A/S Anti-rhesus d recombinant polyclonal antibody and methods of manufacture

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007853A2 (en) * 2004-07-20 2006-01-26 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
WO2007065433A2 (en) * 2005-12-05 2007-06-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
WO2008106980A2 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
WO2008145133A2 (en) * 2007-05-25 2008-12-04 Symphogen A/S Method for manufacturing a recombinant polyclonal protein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BREGENHOLT SOREN ET AL: "Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 12, no. 16, 1 January 2006 (2006-01-01), pages 2007 - 2015, XP008080864, ISSN: 1381-6128 *
MEJFAS ASUNCION ET AL: "Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: Time versus potency", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 49, no. 11, 1 November 2005 (2005-11-01), pages 4700 - 4707, XP002444035, ISSN: 0066-4804 *
RESPIGAN PRESCRIPTION INFORMATION: "RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) (RSV-IGIV)", INTERNET CITATION, XP002444042, Retrieved from the Internet <URL:http://www.medimmune.com/pdf/products/respigam_pi.pdf> [retrieved on 20070725] *
SASTRE PATRICIA ET AL: "Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation", JOURNAL OF MEDICAL VIROLOGY, ALAN R. LISS, NEW YORK, NY, vol. 76, no. 2, 1 June 2005 (2005-06-01), pages 248 - 255, XP002444395, ISSN: 0146-6615 *

Also Published As

Publication number Publication date
AU2008295248A1 (en) 2009-03-12
US20120009623A1 (en) 2012-01-12
RU2010113510A (en) 2011-10-20
WO2009030237A2 (en) 2009-03-12
CA2695309A1 (en) 2009-03-12
BRPI0817079A2 (en) 2016-10-11
ZA201000756B (en) 2010-10-27
EP2185590A2 (en) 2010-05-19
JP2011514139A (en) 2011-05-06
KR20100087283A (en) 2010-08-04
TW200925279A (en) 2009-06-16
MX2010002044A (en) 2010-03-18
US20090137003A1 (en) 2009-05-28
CN101821289A (en) 2010-09-01

Similar Documents

Publication Publication Date Title
WO2009030237A3 (en) Methods for recombinant manufacturing of anti-rsv antibodies
WO2008145133A3 (en) Method for manufacturing a recombinant polyclonal protein
WO2004061104A3 (en) Method for manufacturing recombinant polyclonal proteins
WO2009105150A3 (en) Method of making hybrid cells that express useful antibodies
WO2013061098A3 (en) Functional isotype switching of chimaeric antibody chains &amp; chimaeric animals expressing different igh isotypes
EP4289944A3 (en) Method for preparing genetically-modified t cells which express chimeric antigen receptor
WO2007056994A8 (en) Method for the production of permanent human cell lineages
WO2009126858A3 (en) Materials and methods for improved immunoglycoproteins
WO2014146074A3 (en) Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
WO2011002727A9 (en) Methods of producing humanized non-human mammals
WO2007084364A3 (en) Improved il-12 for expression in mammalian cells
WO2008154014A3 (en) A method for culturing mammalian cells to improve recombinant protein production
EP2808393A3 (en) Fucosylation-deficient cells
WO2009114702A3 (en) Recombinant production of authentic human proteins using human cell expression systems
WO2014097113A3 (en) Production of therapeutic proteins in genetically modified mammalian cells
WO2009139930A3 (en) Antibodies and processes for preparing the same
RU2013132448A (en) METHOD FOR PRODUCING PROTEIN
WO2007130543A3 (en) Method for producing stable mammalian cell lines producing high levels of recombinant proteins
WO2004111194A3 (en) Method to increase protein production in culture
MX355625B (en) Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides.
WO2012178150A3 (en) Methods for developing antigen-specific antibody-producing cell lines and monoclonal antibodies
WO2007056062A3 (en) Methods for adapting mammalian cells
EP2262834A4 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
SG151159A1 (en) Novel expression vector with enhanced gene expression capacity and method for using the same
EP1916298A4 (en) Method for production of antibody

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880106131.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08784476

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 203303

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008295248

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 583066

Country of ref document: NZ

Ref document number: 2695309

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008295248

Country of ref document: AU

Date of ref document: 20080904

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/002044

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008784476

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010523277

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2268/DELNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20107007563

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010113510

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0817079

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100308